Alderman C P, Hundertmark J D, Soetratma T W
Pharmacy Department, Repatriation General Hospital, Daw Park, Australia.
Aust N Z J Psychiatry. 1997 Aug;31(4):601-3. doi: 10.3109/00048679709065084.
To report two cases of perhexiline toxicity associated with selective serotonin re-uptake inhibitor (SSRI) treatment.
Serum perhexiline concentrations progressively increased after a 69-year-old man was concurrently prescribed paroxetine for the treatment of depression. An 84-year-old woman was admitted to hospital with severe, symptomatic perhexiline toxicity associated with fluoxetine treatment.
In both cases, perhexiline therapy was suspended and treatment with SSRIs was withdrawn.
Serum perhexiline concentrations declined following the withdrawal of paroxetine in one case, but in the case of the second patient perhexiline concentrations were extremely slow to decrease, resulting in referral to a rehabilitative care unit for convalescence.
Serum perhexiline concentrations may be elevated during concurrent treatment with SSRIs, potentially resulting in severe toxicity.
报告两例与选择性5-羟色胺再摄取抑制剂（SSRI）治疗相关的哌克昔林中毒病例。
一名69岁男性在同时服用帕罗西汀治疗抑郁症后，血清哌克昔林浓度逐渐升高。一名84岁女性因与氟西汀治疗相关的严重、有症状的哌克昔林中毒入院。
两例患者均停用了哌克昔林治疗，并停用了SSRI治疗。
一例患者停用帕罗西汀后血清哌克昔林浓度下降，但另一例患者哌克昔林浓度下降极为缓慢，因此转至康复护理病房进行康复治疗。
在与SSRI同时治疗期间，血清哌克昔林浓度可能会升高，有可能导致严重中毒。
